Briakinumab

Jump to navigation Jump to search

{{#invoke:Infobox|infobox}}{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= component1= component2= component3= component4= component5= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_US= pregnancy_AU_comment= pregnancy_US_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= QID= QID2= |cat=Chemical articles with unknown parameter in Infobox drug |format=0|errNS=0

|preview=

@@@ (See parameter list). This message only shows in Preview, it will not show after you do Publish changes.

}}Expression error: Unrecognized punctuation character "{".Expression error: Unrecognized punctuation character "{".Expression error: Unrecognized punctuation character "{".

WikiDoc Resources for Briakinumab

Articles

Most recent articles on Briakinumab

Most cited articles on Briakinumab

Review articles on Briakinumab

Articles on Briakinumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Briakinumab

Images of Briakinumab

Photos of Briakinumab

Podcasts & MP3s on Briakinumab

Videos on Briakinumab

Evidence Based Medicine

Cochrane Collaboration on Briakinumab

Bandolier on Briakinumab

TRIP on Briakinumab

Clinical Trials

Ongoing Trials on Briakinumab at Clinical Trials.gov

Trial results on Briakinumab

Clinical Trials on Briakinumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Briakinumab

NICE Guidance on Briakinumab

NHS PRODIGY Guidance

FDA on Briakinumab

CDC on Briakinumab

Books

Books on Briakinumab

News

Briakinumab in the news

Be alerted to news on Briakinumab

News trends on Briakinumab

Commentary

Blogs on Briakinumab

Definitions

Definitions of Briakinumab

Patient Resources / Community

Patient resources on Briakinumab

Discussion groups on Briakinumab

Patient Handouts on Briakinumab

Directions to Hospitals Treating Briakinumab

Risk calculators and risk factors for Briakinumab

Healthcare Provider Resources

Symptoms of Briakinumab

Causes & Risk Factors for Briakinumab

Diagnostic studies for Briakinumab

Treatment of Briakinumab

Continuing Medical Education (CME)

CME Programs on Briakinumab

International

Briakinumab en Espanol

Briakinumab en Francais

Business

Briakinumab in the Marketplace

Patents on Briakinumab

Experimental / Informatics

List of terms related to Briakinumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.<ref>{{#invoke:citation/CS1|citation |CitationClass=news }}</ref>

Like ustekinumab, the antibody targets the interleukins 12 and 23.<ref>PMID 19569977 (Page Template:Module:Citation/CS1/styles.css has no content.{{#invoke:Catalog lookup link|main}})
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand</ref>

Discovery

The candidate drug was discovered by Cambridge Antibody Technology in collaboration with Abbott.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref>MedImmune: External R&D Partnering</ref>

Trials

As of November 2009, Phase III clinical trials for plaque psoriasis<ref>Clinical trial number NCT00570986 for "A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis" at ClinicalTrials.gov</ref><ref>Clinical trial number NCT00691964 for "Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis" at ClinicalTrials.gov</ref> and a Phase II trial for multiple sclerosis<ref>Clinical trial number NCT00086671 for "Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)" at ClinicalTrials.gov</ref> have been completed, and a Phase II trial for Crohn's disease is underway.<ref>Clinical trial number NCT00562887 for "Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease" at ClinicalTrials.gov</ref>

Briakinumab was compared to etanercept and placebo in several double-blind trials. The Psoriasis Area Severity Index (PASI) was reduced significantly better than under the comparator treatments. 81–82% of patients under briakinumab, 40–56% under etanercept, and 7% under placebo reached PASI reduction of at least 75%.<ref>Abbott Press Release: Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874)</ref> No head-to-head studies against ustekinumab, the other IL-12/23 inhibitor, are available.

On January 15, 2011, Abbott announced the withdrawal of its application to the US FDA and European regulators for briakinumab. Following feedback from regulatory authorities indicating the need for further analysis, including the potential for additional studies, Abbott withdrew its applications and was evaluating next steps including possible resubmission at a later date. This compound has never been resubmitted for approval.

Royalties

This is the second candidate from a deal with Cambridge Antibody Technology that Abbott have taken to late-stage clinical trials. As a result of the protracted royalty dispute over Humira Abbott agreed to pay CAT a reduced royalty of 4.75% on any future sales of ABT-874, from which CAT will pay a portion to the MRC and other licensors (according to CAT's 1997 agreement with the MRC).<ref>The Free Library: Cambridge Antibody Technology and Abbott Agree Regarding Royalties</ref>

References

<references group="" responsive="0"></references>

{{#invoke:Check for unknown parameters|check|unknown=|preview=Page using Template:Reflist with unknown parameter "_VALUE_"|ignoreblank=y| 1 | colwidth | group | liststyle | refs }}